Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
LATEST NEWS FROM NASCENT BIOTECH
